Edwards Keeps TAVR Going During COVID-19 Surge

Fourth-quarter sales of Edwards Sapien transcatheter aortic valve systems grew 2% year-over-year overall, despite the intense challenges created by COVID-19.

Post pandemic vision; economic outlook after Coronavirus COVID-19 crisis concept
• Source: shutterstock.com

Edwards Lifesciences expects transcatheter aortic valve replacement (TAVR) procedure volumes to drop in the first quarter of 2021 before “normalizing” by the middle of 2021 as the pandemic begins to subside.

“We really do have confidence that [procedure volumes are] going to come back. We think it’s going to be ramped up during the course of the year,” Edwards CEO Michael...

More from Cardiology

More from Device Area